Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Wettersten, Hiromi I ^a   Landesman, Yosef ^c   Friedlander, Sharon ^c   Shacham, Sharon ^c   Kauffman, Michael ^c   Weiss, Robert H ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Karyopharm Therapeutics   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; EXPORTIN 1; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOTRANSFERASE; POLOXAMER; POVIDONE; PROTEIN P21; SELINEXOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; CELL RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; SMALL INTERFERING RNA; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN LOCALIZATION; RENAL CANCER CELL LINE; TUMOR XENOGRAFT; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINT; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DRUG APPROVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EPITHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; TUMOR CELL LINE; UNITED STATES;

ACTIVE TRANSPORT, CELL NUCLEUS; ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; HYDRAZINES; KARYOPHERINS; KIDNEY NEOPLASMS; MALE; MICE, NUDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, SMALL INTERFERING; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914694787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113867     Document Type: Article

References (22)

1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, et al. (2011) The epidemiology of renal cell carcinoma. Eur Urol 60: 615-621.
2. Weiss RH, Lin PY (2006) Kidney cancer: identification of novel targets for therapy. Kidney Int 69: 224-232.
3. Nelson EC, Evans CP, Lara PN Jr (2007) Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33: 299-313.
4. Wettersten HI, Weiss RH (2013) Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol 10: 336-344.
5. Jung YS, Qian Y, Chen X (2010) Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 22: 1003-1012.
6. Dong Y, Chi SL, Borowsky AD, Fan Y, Weiss RH (2004) Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal 16: 263-269.
7. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, et al. (2000) Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 7: 721-728.
8. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, et al. (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18: 1223-1234.
9. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, et al. (2007) p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 177: 63-68; discussion 68-69.
10. Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, et al. (2001) Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. Eur J Cancer 37: 2405-2412.
11. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, et al. (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120: 3594-3605.
12. Senapedis WT, Baloglu E, Landesman Y (2014) Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 27: 74-86.
13. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, et al. (2013) CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 189: 2317-2326.
14. Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH (2011) Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer biology & therapy 12.
15. Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, et al. (2012) Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 11: 1510-1517.
16. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716.
17. Cowey CL, Hutson TE (2010) Molecularly targeted agents for renal cell carcinoma: the next generation. Clin Adv Hematol Oncol 8: 357-360, 361-354.
18. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, et al. (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14: 4726-4734.
19. Turner JG, Sullivan DM (2008) CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15: 2648-2655.
20. Shen A, Wang Y, Zhao Y, Zou L, Sun L, et al. (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65: 153-159; discussion 159-160.
21. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, et al. (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32: E315.
22. Naniwa J, Kigawa J, Akeshima R, Kanamori Y, Itamochi H, et al. (2003) Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cancer Sci 94: 1099-1103.